EA201692305A1 - Антибактериальные хиназолин-4(3н)-оновые производные - Google Patents

Антибактериальные хиназолин-4(3н)-оновые производные

Info

Publication number
EA201692305A1
EA201692305A1 EA201692305A EA201692305A EA201692305A1 EA 201692305 A1 EA201692305 A1 EA 201692305A1 EA 201692305 A EA201692305 A EA 201692305A EA 201692305 A EA201692305 A EA 201692305A EA 201692305 A1 EA201692305 A1 EA 201692305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
halogen
antibacterial
hinazolin
derivatives
alkoxy
Prior art date
Application number
EA201692305A
Other languages
English (en)
Inventor
Жан-Кристоф Говен
Жан-Филипп Сюриве
Галль Шапо
Азели Мирре
Original Assignee
Актелион Фармасьютиклз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Актелион Фармасьютиклз Лтд. filed Critical Актелион Фармасьютиклз Лтд.
Publication of EA201692305A1 publication Critical patent/EA201692305A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к антибактериальным соединениям формулы Iгде Rозначает Н или галоген; Rозначает группу М; Rозначает Н или галоген; М означает Мили Mгде А означает связь или С≡С; Rозначает Н или галоген; Rозначает Н, алкокси или галоген; Rозначает Н, алкокси, гидроксиалкокси, гидроксиалкил, 1,2-дигидроксиэтил, диалкиламино, 1-гидроксиметилциклопроп-1-ил, 1-((диметилглицил)окси)метилциклопроп-1-ил, 3-гидроксиоксетан-3-ил, морфолин-4-илалкил или морфолин-4-илалкокси; Rозначает группу согласно определению, приведенному в п.1; и их солям.
EA201692305A 2014-05-16 2015-05-13 Антибактериальные хиназолин-4(3н)-оновые производные EA201692305A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14168718 2014-05-16
PCT/EP2015/060653 WO2015173329A1 (en) 2014-05-16 2015-05-13 Antibacterial quinazoline-4(3h)-one derivatives

Publications (1)

Publication Number Publication Date
EA201692305A1 true EA201692305A1 (ru) 2017-05-31

Family

ID=50731968

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692305A EA201692305A1 (ru) 2014-05-16 2015-05-13 Антибактериальные хиназолин-4(3н)-оновые производные

Country Status (19)

Country Link
US (1) US9796686B2 (ru)
EP (1) EP3143007B1 (ru)
JP (1) JP2017515906A (ru)
KR (1) KR20170005105A (ru)
CN (1) CN106458931A (ru)
AR (1) AR100428A1 (ru)
AU (1) AU2015261540A1 (ru)
BR (1) BR112016026787A8 (ru)
CA (1) CA2948077A1 (ru)
CL (1) CL2016002918A1 (ru)
EA (1) EA201692305A1 (ru)
ES (1) ES2687040T3 (ru)
IL (1) IL248922A0 (ru)
MX (1) MX2016014989A (ru)
PH (1) PH12016502253A1 (ru)
SG (1) SG11201609286VA (ru)
TW (1) TW201625559A (ru)
WO (1) WO2015173329A1 (ru)
ZA (1) ZA201608680B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
JP6407288B2 (ja) 2013-12-19 2018-10-17 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 抗菌性１ｈ−インダゾール及び１ｈ−インドール誘導体
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
MX2018002479A (es) * 2015-08-28 2018-06-15 Idorsia Pharmaceuticals Ltd Derivados antibacterianos pirrolidin-2-ona anulados.
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
AU2016367510A1 (en) * 2015-12-08 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Substituted benzazinones as antibacterial compounds
IL285318B (en) 2016-04-01 2022-09-01 Kalyra Pharmaceuticals Inc Estrogen receptor modulators
RU2722594C1 (ru) * 2016-09-28 2020-06-02 Тон-А Ст Ко., Лтд. Производные тетрагидропиридина и их использование в качестве антибактериальных средств
AU2020326691A1 (en) 2019-08-06 2022-03-03 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337298A (en) 1997-02-27 2002-11-26 American Cyanamid Co N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
EP2662353A3 (en) * 2007-06-12 2014-04-02 Achaogen, Inc. Antibacterial agents
WO2010024356A1 (ja) 2008-08-27 2010-03-04 大正製薬株式会社 ナフチリジン－ｎ－オキシドを有する新規ヒドロキサム酸誘導体
JP2012504556A (ja) 2008-10-03 2012-02-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
DE102008044132A1 (de) 2008-11-27 2010-06-02 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät mit zweiseitig anschlagbarer Tür
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CA2774250C (en) 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
WO2011073845A1 (en) * 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
US8765773B2 (en) 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
MX2013005200A (es) 2010-11-10 2013-06-28 Achaogen Inc Derivados de acido hidroxamico y su so en el tratamiento de infecciones bacterianas.
CN103328482A (zh) 2011-01-03 2013-09-25 韩美药品株式会社 用于调节g蛋白-偶联受体的新双环化合物
BR112013022536B1 (pt) * 2011-03-07 2020-05-26 Pfizer, Inc. Derivados flúor-piridinona, suas composições farmacêuticas e usos como agentes antibacterianos
SG193367A1 (en) 2011-04-08 2013-10-30 Pfizer Isoxazole derivatives useful as antibacterial agents
EP2694481B1 (en) 2011-04-08 2015-12-30 Pfizer Inc Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
CA2837883C (en) 2011-06-08 2019-10-29 Sunovion Pharmaceuticals, Inc. Metabotropic glutamate receptor 5 modulators and methods of use thereof
EP2847162A1 (en) 2012-05-09 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2013170165A1 (en) * 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
AU2014306451B2 (en) 2013-08-16 2019-01-17 Duke University Substituted hydroxamic acid compounds
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
JP6407288B2 (ja) 2013-12-19 2018-10-17 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 抗菌性１ｈ−インダゾール及び１ｈ−インドール誘導体
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona

Also Published As

Publication number Publication date
PH12016502253A1 (en) 2017-01-16
CN106458931A (zh) 2017-02-22
US9796686B2 (en) 2017-10-24
ES2687040T3 (es) 2018-10-23
ZA201608680B (en) 2018-11-28
IL248922A0 (en) 2017-01-31
EP3143007A1 (en) 2017-03-22
TW201625559A (zh) 2016-07-16
KR20170005105A (ko) 2017-01-11
WO2015173329A1 (en) 2015-11-19
CL2016002918A1 (es) 2017-04-07
BR112016026787A8 (pt) 2017-12-26
EP3143007B1 (en) 2018-07-11
MX2016014989A (es) 2017-03-31
AU2015261540A1 (en) 2017-01-12
SG11201609286VA (en) 2016-12-29
CA2948077A1 (en) 2015-11-19
JP2017515906A (ja) 2017-06-15
BR112016026787A2 (ru) 2017-08-15
US20170081292A1 (en) 2017-03-23
AR100428A1 (es) 2016-10-05

Similar Documents

Publication Publication Date Title
EA201692305A1 (ru) Антибактериальные хиназолин-4(3н)-оновые производные
CY1124537T1 (el) Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201792639A1 (ru) ПИРРОЛО[1.2-f][1.2.4]ТРИАЗИНЫ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫХ ВИРУСНЫХ ИНФЕКЦИЙ
MA40301A1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
BR112017006253A2 (pt) novos compostos
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
EA201600248A1 (ru) Антибактериальные производные 2h-индазола
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
EA201792021A1 (ru) Ингибитор jak
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201691141A1 (ru) Соединения против ccr6
CR20150268A (es) Compuestos novedosos
EA201690844A1 (ru) Ингибиторы gsk-3
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
EA201691775A1 (ru) Производные 1,2-дигидро-3н-пирроло[1,2-с]имидазол-3-она и их применение в качестве антибактериальных средств
EA201891391A1 (ru) Диастереоселективный синтез фосфатных производных и пролекарства гемцитабина nuc-1031
JO3318B1 (ar) مثبطات bace
EA201790234A1 (ru) 2'-хлораминопиримидиноновые и пиримидиндионовые нуклеозиды
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
EA201491276A1 (ru) Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2